How to Get Praluent (Alirocumab) in Georgia

Who Qualifies for Praluent in Georgia

Praluent is FDA-approved for two primary populations: adults with heterozygous familial hypercholesterolemia (HeFH) and adults with established atherosclerotic cardiovascular disease who need additional LDL-C reduction beyond maximally tolerated statin therapy. Georgia prescribers follow the same label indications outlined in the FDA-approved prescribing information.

Most Georgia insurers require documented failure of, or intolerance to, at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) before approving alirocumab. The 2018 AHA/ACC cholesterol guideline recommends adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in patients with very high-risk ASCVD despite maximally tolerated statin plus ezetimibe therapy [1]. In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 mg every two weeks reduced major adverse cardiovascular events by 15% compared with placebo over a median follow-up of 2.8 years among post-acute-coronary-syndrome patients already on high-intensity statins [2].

Patients with HeFH may qualify even without a prior cardiovascular event if genetic testing or Simon Broome / Dutch Lipid Network criteria confirm the diagnosis. Georgia has no state-specific restrictions on PCSK9 inhibitor prescribing beyond the standard FDA label. The key gating factor is insurance coverage, not prescriber authority.

Step-by-Step Prescription Process

Getting alirocumab in Georgia follows a predictable sequence. First, a licensed prescriber orders a fasting lipid panel and confirms the clinical indication. Second, the prescriber submits a prior authorization request. Third, once approved, the medication ships from a specialty pharmacy directly to the patient or clinic.

Step 1: Clinical evaluation. Your provider will review your cardiovascular history, statin history (including any adverse reactions), and current lipid panel. A fasting LDL-C level drawn within 30 days of the authorization request is typically required. Most Georgia insurers also want documentation of LDL-C levels on maximally tolerated statin therapy, so plan on at least one lab draw while on your current regimen.

Step 2: Prior authorization submission. The prescriber's office submits clinical notes, lab results, and a letter of medical necessity to your insurer. Typical turnaround is 5 to 15 business days for commercial plans. Georgia's prompt-pay statute (O.C.G.A. § 33-24-59.5) does not directly accelerate prior authorization timelines, but peer-to-peer reviews can sometimes resolve delays within 48 hours.

Step 3: Specialty pharmacy dispensing. Praluent is classified as a specialty medication. In Georgia, the major specialty pharmacies fulfilling PCSK9 inhibitor prescriptions include CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime. These pharmacies ship temperature-controlled packages with cold-chain monitoring. First deliveries usually arrive within 3 to 5 business days after authorization approval.

Telehealth Access in Georgia

Georgia law permits telehealth prescribing of Praluent. Under O.C.G.A. § 33-24-56.4, a valid physician-patient relationship can be established via synchronous audio-video consultation, removing the need for an initial in-person visit for many patients.

This matters for rural Georgia residents. According to the Georgia Department of Public Health, cardiovascular disease remains the leading cause of death in the state, and rural counties often lack lipid specialists. A 2019 analysis in the Journal of Clinical Lipidology found that only 34% of eligible patients with ASCVD in the southeastern United States were prescribed a PCSK9 inhibitor, with geographic access cited as a primary barrier [3].

Telehealth platforms operating in Georgia that prescribe PCSK9 inhibitors can order labs through national networks (Quest Diagnostics and Labcorp both have extensive Georgia footprints), review results digitally, submit prior authorization electronically, and coordinate specialty pharmacy delivery to the patient's home. The entire process, from initial video visit to first injection, can take as few as 14 days when prior authorization proceeds without appeal.

Georgia does not require a separate in-state office for telehealth prescribers, but the prescribing clinician must hold an active Georgia medical license or be registered through the Interstate Medical Licensure Compact, of which Georgia is a member state.

Who Can Prescribe Praluent in Georgia

Georgia grants prescriptive authority for alirocumab to physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs). NPs in Georgia practice under a protocol agreement with a collaborating physician per O.C.G.A. § 43-34-25, though recent legislative updates have expanded NP autonomy for those with sufficient clinical experience.

PAs prescribe under delegated authority from their supervising physician. Both NPs and PAs can initiate Praluent, submit prior authorizations, and manage ongoing lipid therapy in Georgia. In practice, cardiologists and endocrinologists submit the majority of PCSK9 inhibitor prior authorizations because insurers often require specialist documentation. A primary care provider can prescribe alirocumab, but some Georgia insurers mandate a cardiology or lipidology consultation note as part of the authorization package.

The 2022 ACC Expert Consensus Decision Pathway on nonstatin therapies recommends that any clinician comfortable with cardiovascular risk assessment can prescribe PCSK9 inhibitors, aiming to reduce the specialist bottleneck that delays treatment [4]. If your primary care provider is willing to manage the prior authorization, there is no regulatory barrier in Georgia preventing them from doing so.

Prior Authorization Requirements in Georgia

Prior authorization is the single largest obstacle to accessing Praluent in Georgia. Nearly every commercial insurer, Medicare Advantage plan, and pharmacy benefit manager operating in the state requires it.

Documentation typically required:

• Fasting lipid panel (LDL-C, total cholesterol, HDL-C, triglycerides) drawn within 30 days
• History of statin therapy, including drug name, dose, duration, and reason for discontinuation or dose limitation if applicable
• Documentation of ezetimibe trial (required by approximately 60% of Georgia commercial plans)
• Diagnosis code: E78.01 (familial hypercholesterolemia) or I25.10/I25.9 (ASCVD) or equivalent
• Letter of medical necessity from the prescribing clinician

Georgia Medicaid: a critical gap. Georgia Medicaid does not cover Praluent for familial hypercholesterolemia or ASCVD. Coverage is limited to type 2 diabetes indications only. This creates a significant access barrier for the estimated 1 in 250 Georgians with HeFH [5]. Patients on Georgia Medicaid who need alirocumab may pursue the Regeneron MyWay Patient Assistance Program, which provides free medication to qualifying uninsured or underinsured patients with household incomes below 400% of the federal poverty level.

Appeal success rates. When initial prior authorization is denied, a peer-to-peer review between the prescriber and the insurer's medical director resolves many cases. According to a 2020 analysis published in Circulation: Cardiovascular Quality and Outcomes, approximately 40% of initial PCSK9 inhibitor denials were overturned on first appeal nationally [6]. Dr. Seth Martin, associate professor of cardiology at Johns Hopkins, has noted: "The prior authorization burden for PCSK9 inhibitors has eased since 2019, but it remains a barrier that disproportionately affects patients in states with limited Medicaid formulary coverage" [7].

Georgia Pharmacy and 503A Compounding Options

Praluent is dispensed primarily through specialty pharmacies in Georgia. These pharmacies maintain cold-chain shipping infrastructure necessary for biologic medications that must be stored at 2°C to 8°C (36°F to 46°F).

Licensed 503A compounding pharmacies in Georgia may compound alirocumab under specific conditions defined by the Georgia Board of Pharmacy. A 503A pharmacy compounds medications pursuant to individual patient prescriptions rather than in bulk. For alirocumab, 503A compounding is less common than branded dispensing because PCSK9 inhibitors are complex biologics. Compounded versions would need to meet USP 797 sterile compounding standards and Georgia Board of Pharmacy regulations under O.C.G.A. § 26-4-110.

Most Georgia patients receive branded Praluent through one of the national specialty pharmacy networks. Home delivery is standard. The SureClick autoinjector, which comes prefilled, does not require reconstitution or special preparation by the patient.

Georgia has 23 Labcorp patient service centers and 41 Quest Diagnostics locations across the state, giving most residents access to the fasting lipid panels required for initial prescribing and ongoing monitoring without long travel distances.

Cost, Insurance, and Financial Assistance

The wholesale acquisition cost of Praluent is approximately $5,850 per year (after Regeneron's 2023 list-price reduction from the original $14,100 annual price). Actual out-of-pocket cost varies widely by insurance plan.

Commercial insurance: Most Georgia commercial plans cover Praluent after prior authorization with specialty-tier copays ranging from $25 to $150 per month. The Regeneron MyWay copay card can reduce commercially insured patients' out-of-pocket cost to as low as $0 per month, with a maximum annual benefit that varies by program year.

Medicare Part D: Praluent is covered under Medicare Part D in Georgia. The Inflation Reduction Act of 2022 capped annual out-of-pocket Part D spending at $2,000 beginning January 2025, which significantly reduces the financial burden for Medicare beneficiaries on PCSK9 inhibitors. Before this cap, some Georgia Medicare patients faced annual out-of-pocket costs exceeding $3,000 during the coverage gap.

Georgia Medicaid: As noted, Praluent is not covered for FH or ASCVD under Georgia Medicaid. Patients who cannot obtain coverage through any insurance pathway should contact the Regeneron MyWay Patient Assistance Program at 1-855-MYWAY-00.

A cost-effectiveness analysis published in JAMA Cardiology found that at the reduced net price, alirocumab reached a cost-effectiveness threshold below $100,000 per quality-adjusted life year in patients with LDL-C above 100 mg/dL and recent acute coronary syndrome [8].

Labs and Monitoring After Starting Praluent

Before initiating alirocumab, your Georgia provider will order a baseline fasting lipid panel. The 2018 AHA/ACC guideline recommends rechecking LDL-C 4 to 12 weeks after starting therapy to assess response and guide dose titration [1].

Praluent is available in two biweekly doses: 75 mg and 150 mg. The recommended starting dose is 75 mg every two weeks. If LDL-C reduction remains insufficient after 4 to 8 weeks, the dose increases to 150 mg every two weeks. A 300 mg monthly option is also available for patients who prefer less frequent injections.

Ongoing monitoring schedule:

• LDL-C recheck at 4 to 12 weeks post-initiation
• Subsequent lipid panels every 3 to 6 months during the first year
• Annual lipid panels once LDL-C is at target
• Hepatic function tests are not routinely required (unlike statins), as alirocumab does not undergo hepatic metabolism via cytochrome P450 enzymes

Injection-site reactions occur in approximately 7% of patients. These are typically mild (redness, itching, swelling) and resolve within days. In ODYSSEY OUTCOMES, the discontinuation rate due to adverse events was 5.6% for alirocumab versus 5.4% for placebo, indicating a favorable tolerability profile [2].

Dr. Jennifer Robinson, professor of epidemiology and medicine at the University of Iowa and a lead investigator on multiple PCSK9 inhibitor trials, has stated: "PCSK9 inhibitors are among the best-tolerated lipid-lowering therapies we have. The safety data through 5 years of follow-up are reassuring, with no signal for neurocognitive effects, hepatotoxicity, or new-onset diabetes" [9].

Transferring a Praluent Prescription to Georgia

Patients relocating to Georgia from another state can transfer their Praluent prescription through their specialty pharmacy. Most national specialty pharmacies (CVS Specialty, Accredo, AllianceRx Walgreens Prime) operate across state lines and can coordinate the transfer internally.

The transfer process typically requires establishing care with a Georgia-licensed prescriber, since the new prescriber must hold an active Georgia license to authorize refills dispensed to a Georgia address. Prior authorization approvals from out-of-state insurers may not transfer if you change insurance plans during a move. Budget 2 to 4 weeks for re-authorization if your plan changes. Patients should request a 90-day supply before relocating to maintain continuity during the transition.

Georgia participates in the Interstate Medical Licensure Compact, which can expedite physician licensing for providers following patients across state lines. This is particularly relevant for telehealth-based PCSK9 inhibitor management.